|
|||
|
Priv.-Doz. Dr. med. univ. Beatrice Schuler-Thurner
|
|
Research Interests:
Malignant Melanoma, vaczination therapy with dendritic cells
Selected References:
Krug C.; Schmidt P.; Chmielewski M.; et al. Retargeting T cells with MHC-independent chimeric antigen receptors by RNA electroporation. EXPERIMENTAL DERMATOLOGY 2012,21,3,e27-e27
Gross S.; Hamann A.; Leisgang W.; et al. New lessons learned from cancer immunotherapy: tumor-specific CD4+Tcells frequently expand and react to short peptides. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 2011,9,9,770-771
Debey-Pascher Svenja; Hofmann Andrea; Kreusch Fatima; et al. RNA-Stabilized Whole Blood Samples but Not Peripheral Blood Mononuclear Cells Can Be Stored for Prolonged Time Periods Prior to Transcriptome Analysis. JOURNAL OF MOLECULAR DIAGNOSTICS 2011,13,4,452-460
de Vries I. Jolanda M.; Castelli Chiara; Huygens Caroline; et al. Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents. CLINICAL CANCER RESEARCH 2011,17,4,841-848
Birkholz K.; Pfeiffer I.; Schwenkert M.; et al. DEC-205 targeting of dendritic cells: a challenging approach of antigen loading. EXPERIMENTAL DERMATOLOGY 2011,20,2,184-184
Doerrie J.; Schaft N.; Moritz T.; et al. Designer DC as anti-melanoma vaccine: finding the right time to prime. EXPERIMENTAL DERMATOLOGY 2011,20,2,184-184
Gross S.; Schmid M.; Schierer S.; et al. Altered migration of E/L-Selectin expressing DC - a monitoring challenge. EXPERIMENTAL DERMATOLOGY 2011,20,2,188-189
Schuler-Thurner B.; Erdmann M.; Voland S.; et al. Vaccination with class I and II tumor peptide-loaded, cocktail-matured monocyte-derived DCs demonstrates solid immunogenicity and prolonged survival in a subset of melanoma patients exhibiting a particular gene expression profile. EXPERIMENTAL DERMATOLOGY 2011,20,2,188-188
Voland S.; Gross S.; Schuler-Thurner B.; et al. Characterisation and functional analysis of T-cell responses in melanoma patients vaccinated with peptide-loaded dendritic cells. EXPERIMENTAL DERMATOLOGY 2011,20,2,189-189
Birkholz Katrin; Schwenkert Michael; Kellner Christian; et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. BLOOD 2010,116,13,2277-2285
Gross S.; Hamann A.; Schuler-Thurner B.; et al. Monitoring of vaccine-specific cytolytic, helper and regulatory T cells in melanoma patients after vaccination with autologous antigen-loaded dendritic cells. EXPERIMENTAL DERMATOLOGY 2010,19,2,189-189
Erfurt-Berge C.; Schuler-Thurner B.; Mahler V.; et al. Unexpected induction of delayed type hypersensitivity (DTH) to human serum albumin in melanoma patients by Dendritic Cell vaccination. EXPERIMENTAL DERMATOLOGY 2010,19,2,207-207
Schliep S.; Schliep K.; Erdmann M.; et al. Comparison of the serum tumor markers S100 and melanoma inhibitory activity (MIA) in the monitoring of melanoma patients undergoing dendritic cell vaccination. EXPERIMENTAL DERMATOLOGY 2010,19,2,221-221
Gross S.; Hamann A.; Leisgang W.; et al. Getting T cells to work EUR+ transforming quantity into quality. EXPERIMENTAL DERMATOLOGY 2009,18,3,298-298
Connerotte, T., Van Pel, A., Godelaine, D., Tartour, E., Schuler-Thurner, B., Lucas, S., Thielemans, K., Schuler, G., and Coulie, P. G. (2008). Functions of anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Research 68, 3931-3940.
Erdmann, M., Haendle, I., Schmitt-Haendle, M., Leisgang, W., Trump, S., Wiesinger, M., Theiner, G., Kaempgen, E., Schuler-Thurner, B., and Schuler, G. (2008). Comparison of immune responses after vaccination with tumour-peptide-loaded dendritic cells with or without prior denileukin diftitox treatment in metastasized malignant melanoma. Experimental Dermatology 17, 267.
Erfurt, C., Haendle, I., Schuler-Thurner, B., Thielemanns, K., van der Bruggen, P., Schuler, G., and Schultz, E. (2008). Broad T cell reactivity against a tumour-associated self antigen in melanoma patients and healthy individuals without obvious signs of autoimmunity. Experimental Dermatology 17, 251.
Haendle, I., Schmitt-Haendle, M., Voland, S., Erdmann, M., Schliep, S., Schaft, N., Doerrie, J., Kaempgen, E., Schuler-Thurner, B., and Schuler, G. (2008). T-cell responses in stage IV melanoma patients vaccinated with dendritic cells electroporated with defined RNA. Experimental Dermatology 17, 263.
Schmitt-Haendle, M., Voland, S., Haendle, I., Kaempgen, E., Schuler-Thurner, B., and Schuler, G. (2008). Naturally occurring T-cell responses against the tumour antigens MageA3, MelanA and Survivin in stage IV melanoma patients. Experimental Dermatology 17, 251.
Schwenkert, M., Birkholz, K., Schwemmlein, M., Kellner, C., Kuegler, M., Peipp, M., Nettelbeck, D. M., Schuler-Thurner, B., Schaft, N., Dorrie, J., Ferrone, S., Kampgen, E., and Fey, G. H. (2008). A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Melanoma Research 18, 73-84.
Erdmann M, Dörrie J, Schaft N, Strasser E, Hendelmeier M, Kämpgen E, Schuler G, Schuler-Thurner B
Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection.
J Immunother. 2007;30(6): 663-74
Korner H, Epanchintsev A, Berking C, Schuler-Thurner B, Speicher MR, Menssen A, Hermeking H.
Digital karyotyping reveals frequent inactivation of the dystrophin/DMD gene in malignant melanoma.
Cell Cycle. 2007 Jan 15;6(2):189-98. Epub 2007 Jan 19.
Erfurt C, Sun Z, Haendle I, Schuler-Thurner B, Heirman C, Thielemans K, van der Bruggen P, Schuler G, Schultz ES.
Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity.
J Immunol. 2007 Jun 15;178(12):7703-9.
Romer W, Nomayr A, Greess H, Fiedler E, Platsch G, Schuler-Thurner B, Pfahlberg A, Hothorn T, Schuler G, Hornegger J, Bautz W, Kuwert T.
Retrospective interactive rigid fusion of (18)F-FDG-PET and CT. Additional diagnostic information in melanoma patients.
Nuklearmedizin. 2006;45(2):88-95.
Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tuttenberg A, Becker JC, Keikavoussi P, Kampgen E, Schuler G.
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Ann Oncol. 2006 Jan 17; [Epub ahead of print]
Schuler-Thurner B, Schuler G.
[Vaccination therapy of melanoma]
J Dtsch Dermatol Ges. 2005 Aug;3(8):630-45. Review. German. No abstract available.
Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, Schuler G.
Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells.
J Immunol Methods. 2005 Mar;298(1-2):61-72. Erratum in: J Immunol Methods. 2005 Aug;303(1-2):152.
Maczek C, Berger TG, Schuler-Thurner B, Schultz ES, Hamann A, Dunbar PR,
Cerundolo V, Steinkasserer A, Schuler G.
Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma
patients.
Int J Cancer. 2005 Jun 20;115(3):450-5.
Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B,
Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G,
Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J,
Enk A, Huber C, Wolfel T.
A phase I vaccination study with tyrosinase in patients with stage II melanoma
using recombinant modified vaccinia virus Ankara (MVA-hTyr).
Cancer Immunol Immunother. 2005 May;54(5):453-67. Epub 2004 Dec 31.
Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G,
Boon T, van der Bruggen P, Colau D.
A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers
in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Eur J Immunol. 2005 Apr;35(4):1066-75.
Roeder C, Schuler-Thurner B, Berchtold S, Vieth G, Driesch P, Schuler G,
Luftl M.
MAGE-A3 is a frequent tumor antigen of metastasized melanoma.
Arch Dermatol Res. 2005 Jan;296(7):314-9. Epub 2004 Nov 27.
Jachimczak P, Apfel R, Bosserhoff AK, Fabel K, Hau P, Tschertner I, Wise P,
Schlingensiepen KH, Schuler-Thurner B, Bogdahn U.
Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA)
by antisense techniques.
Int J Cancer. 2005 Jan 1;113(1):88-92.
Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, Wolfel T.
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).
Cancer Immunol Immunother. 2004 Dec 31; [Epub ahead of print]
Roeder C, Schuler-Thurner B, Berchtold S, Vieth G, Driesch PV, Schuler G, Luftl M.
MAGE-A3 is a frequent tumor antigen of metastasized melanoma.
Arch Dermatol Res. 2004 Nov 27; [Epub ahead of print]
Jachimczak P, Apfel R, Bosserhoff AK, Fabel K, Hau P, Tschertner I, Wise P, Schlingensiepen KH, Schuler-Thurner B, Bogdahn U.
Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques.
Int J Cancer. 2005 Jan 1;113(1):88-92.
Berger TG, Haendle I, Schrama D, Luftl M, Bauer N, Pedersen Ls LO, Schuler-Thurner B, Hohenberger W, Straten Pt P, Schuler G, Becker JC.
Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.
Int J Cancer. 2004 Aug 20;111(2):229-37.
Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G.
Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
J Immunol. 2004 Jan 15;172(2):1304-10.
Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A.
Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
J Immunol. 2003 Nov 1;171(9):4893-7.
Strasser EF, Berger TG, Weisbach V, Zimmermann R, Ringwald J, Schuler-Thurner B, Zingsem J, Eckstein R.
Comparison of two apheresis systems for the collection of CD14+ cells intended to be used in dendritic cell culture.
Transfusion. 2003 Sep;43(9):1309-16.
Schuler G, Schuler-Thurner B, Steinman RM.
The use of dendritic cells in cancer immunotherapy.
Curr Opin Immunol. 2003 Apr;15(2):138-47.
Marovich MA, Mascola JR, Eller MA, Louder MK, Caudrelier PA, El-Habib R, Ratto-Kim S, Cox JH, Currier JR, Levine BL, June CH, Bernstein WB, Robb ML, Schuler-Thurner B, Steinman RM, Birx DL, Schlesinger-Frankel S.
Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.
J Infect Dis. 2002 Nov 1;186(9):1242-52. Epub 2002 Oct 07.
Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, Schuler-Thurner B.
Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories.
J Immunol Methods. 2002 Oct 15;268(2):131-40.
Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G.
Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.
J Exp Med. 2002 May 20;195(10):1279-88. Erratum in: J Exp Med. 2003 Feb 3;197(3):395.
Andersen MH, Keikavoussi P, Brocker EB, Schuler-Thurner B, Jonassen M, Sondergaard I, Straten PT, Becker JC, Kampgen E.
Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression.
Int J Cancer. 2001 Dec 15;94(6):820-4.
Li J, Schuler-Thurner B, Schuler G, Huber C, Seliger B.
Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation.
Int Immunol. 2001 Dec;13(12):1515-23.
Fackler OT, Wolf D, Weber HO, Laffert B, D'Aloja P, Schuler-Thurner B, Geffin R, Saksela K, Geyer M, Peterlin BM, Schuler G, Baur AS.
A natural variability in the proline-rich motif of Nef modulates HIV-1 replication in primary T cells.
Curr Biol. 2001 Aug 21;11(16):1294-9.
Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G.
Dendritic cells as vectors for therapy.
Cell. 2001 Aug 10;106(3):271-4. Review. No abstract available.
Glaser A, Schuler-Thurner B, Feuerstein B, Zingsem J, Zimmermann R, Weisbach V, Eckstein R.
Collection of MNCs with two cell separators for adoptive immunotherapy in patients with stage IV melanoma.
Transfusion. 2001 Jan;41(1):117-22.
Feuerstein B, Berger TG, Maczek C, Roder C, Schreiner D, Hirsch U, Haendle I, Leisgang W, Glaser A, Kuss O, Diepgen TL, Schuler G, Schuler-Thurner B.
A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use.
J Immunol Methods. 2000 Nov 1;245(1-2):15-29.
Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Roder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den Driesch P, Knop J, Brocker EB, Enk A, Kampgen E, Schuler G.
Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells.
J Immunol. 2000 Sep 15;165(6):3492-6.
Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G.
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.
J Exp Med. 1999 Dec 6;190(11):1669-78.
Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G.
Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application.
J Immunol Methods. 1999 Feb 1;223(1):1-15. Review. Erratum in: J Immunol Methods 1999 Apr 22;224(1-2):211.
Schuler G, Thurner B, Romani N.
Dendritic cells: from ignored cells to major players in T-cell-mediated immunity.
Int Arch Allergy Immunol. 1997 Apr;112(4):317-22. Review.
